What makes IO360° so important is that it joins cancer expertise from clinical, business, regulatory, academic and nonprofit communities together with the goal of advancing treatments to enable a patient’s immune system to eradicate cancer faster.
NEW YORK (PRWEB)
September 12, 2019
The Conference Forum has announced that the 6th annual IO360°: Immuno-Oncology 360° Summit will take place on February 26 – 28, 2020 at the Crowne Plaza Times Square Hotel in New York City, NY, with a full day dedicated to Cell & Gene Therapy for Solid Tumors on February 27.
The opening keynotes include IO pioneers and entrepreneurs, Carl June, MD, Director, Center for Cellular Immunotherapies at the Perelman School of Medicine; UPenn and Arie Belldegrun, MD, Executive Chair and Co-founder, Allogene who will address T-cell and CAR-T therapy advancements.
The most prestigious analyst in IO, Andrew Baum, MD, Head of Global Healthcare and Managing Director, Equity Research for Citi will deliver the financial opening keynote on the Evolution and Forecast of the IO Space.
Delivering a cornerstone presentation on New Scientific Frontiers in Cell Therapies for Solid Tumors will be immunotherapy expert Crystal Mackall, MD, Professor of Pediatrics and Medicine and Director of the Stanford Center for Cancer Cell Therapy at Stanford University School of Medicine.
Peter Marks, MD, PhD, Director of the Center for Biologics Evaluation and Research, FDA will be leading a panel discussion on the Evolution of Regulatory Policy for Cell & Gene Therapy.
Joining the program as the 2020 guest keynote is cancer veteran and advocate Jane Perlmutter, PhD, who will participate in a fireside chat to share her remarkable journey with immunotherapy.
New leadership to IO360° includes:
-
Charles Drake, MD, PhD, Columbia University Medical Center - Stephanie Goff, MD, National Cancer Institute
- Stephan Grupp, MD, PhD, Children’s Hospital Of Pennsylvania (CHOP)
- Ramy Ibrahim, MD, Parker Institute for Cancer Immunotherapy
- Beth Metzheiser, BMS
- Annette Schmid, MD, Takeda
- Aiman Shalabi, PharmD, GSK
- Martin Stumpe, PhD, Tempus
- Roman Yelensky, PhD, Gritstone Oncology
Amongst many more
With more than 80 IO topics covered, IO360° is divided into the following plenaries with data presentations and panel discussions on Discovery and Preclinical Science, Translational Science, Clinical Developments, Bispecifics, Biomarkers and Diagnostics, Clinical Operations, AI for Cancer Immunotherapy, Imaging Aspects, Business Developments, and Emerging Technologies.
For the first time, IO360° 2020 features a day dedicated to Cell and Gene Therapy with a focus on solid tumors to take place on February 27. Chairing the Cell & Gene Therapy day will be Aiman Shalabi, PharmD, Vice President of R&D, Cell and Gene Therapies for GSK and will lead the program in addressing the following topics: Landscape and Evolution of the Cell & Gene Therapy Marketplace, New Scientific Frontiers in Cell Therapies for Solid Tumors, Cell Therapy Pivotal Pharma Developments for Solid Tumors, Current and Future Innovations Toward GMP Manufacturing of CAR and TCR Engineered T cells, FDA Led Session on the Evolution of Regulatory Policy for Cell & Gene Therapy, New Collaborative Development Paradigms for Cell Therapies and Cell & Gene Therapy Debates.
“Developing immuno-oncology treatments for patients that could become the standard of care across a wide variety of cancers is still a complex challenge,” said Kate Woda, Director, IO360°. “What makes IO360° so important is that it joins cancer expertise from clinical, business, regulatory, academic and nonprofit communities together with the goal of advancing treatments to enable a patient’s immune system to eradicate cancer faster.”
IO360° will also feature extensive networking opportunities and includes one-on-one partnering to help facilitate business meetings and additional collaborations.
To learn more please visit theconferenceforum.org
About Immuno-Oncology 360˚:
Immuno-Oncology (IO) 360° is the premier meeting across all stakeholders in IO, addressing the rapid advancements of clinical, scientific and business developments of IO in one setting to help develop therapeutics for a wider range of cancers at an accelerated rate. Guided by lead advisors Axel Hoos, MD, PhD, SVP of Oncology R&D, GSK, James Gulley, MD, PhD, Head of Immunotherapy Section and Director of Medical Oncology Service at the Office of the Clinical Director, Center for Cancer Research, NCI, Priti Hegde, MD, Chief Scientific Officer, Foundation Medicine, Andrew Baum, MD, Head of Global Healthcare and Managing Director, Equity Research, Citi, Dan Chen, MD, PhD, Chief Medical Officer, IGM Biosciences, Jacqueline Karmel, Principal International Scientific Director, Roche and Ian McCaffery, VP, Oncology Translational Science, Janssen. The three-day summit features ten plenary sessions, a dedicated day to Cell & Gene Therapy, over 120 speakers and more than ten hours of networking. There will be over 500 attendees representing pharma, biotechs, academia, research organizations, business development and the IO investment community.
About the Conference Forum:
The Conference Forum is a life science industry research firm that develops conferences primarily around how to get therapeutics to patients faster. They examine and challenge the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research with common goals that are patient-focused. They are committed to creating the best content, exchange of ideas and solutions among peers, as well as providing high quality networking.